Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Mohler, James L.; Antonarakis, Emmanuel S.; Armstrong, Andrew J.; D’Amico, Anthony V.; Davis, Brian J.; Dorff, Tanya B.; Eastham, James A.; Enke, Charles Arthur; Farrington, Thomas; Higano, Celestia S.; Horwitz, Eric M.; Hurwitz, Michael; Ippolito, Joseph E.; Kane, Christopher J.; Kuettel, Michael; Lang, Joshua M.; McKenney, Jesse K.; Netto, George J.; Penson, David F.; Plimack, Elizabeth R.; Pow‐Sang, Julio M.; Pugh, Thomas J.; Richey, Sylvia; Roach, Mack; Rosenfeld, Stan; Schaeffer, Edward M.; Shabsigh, Ahmad; Small, Eric J.; Spratt, Daniel E.; Srinivas, Sandy; Tward, Jonathan D.; Shead, Dorothy A.; Freedman-Cass, Deborah A.

doi:10.6004/jnccn.2019.0023

Cited by 998 publications

(795 citation statements)

References 260 publications

Supporting

Mentioning

776

Contrasting

Unclassified

Order By: Relevance

“…According to the National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer patients after radical prostatectomy, 64 PSA measurements should be performed every 6 to 12 months and a digital rectal examination (DRE) is recommended annually for the first 5 years. For PCa patients assigned as high risk by the signature, we suggest that more close follow‐ups, such as PSA testing every 3 months and DRE every 6 months for the first 5 years, maybe better to detect disease progression timely.…”

Section: Discussionmentioning

confidence: 99%

A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy

Huang

Zhang

et al. 2020

The Prostate

View full text Add to dashboard Cite

Background The qualitative transcriptional characteristics, the within‐sample relative expression orderings (REOs) of genes, are highly robust against batch effects and sample quality variations. Hence, we develop a qualitative transcriptional signature based on REOs to predict the biochemical recurrence risk of prostate cancer (PCa) patients after radical prostatectomy. Methods Gene pairs with REOs significantly correlated with the biochemical recurrence‐free survival (BFS) were identified from 131 PCa samples in the training data set. From these gene pairs, we selected a qualitative transcriptional signature based on the within‐sample REOs of gene pairs which could predict the recurrence risk of PCa patients after radical prostatectomy. Results A signature consisting of 74 gene pairs, named 74‐GPS, was developed for predicting the recurrence risk of PCa patients after radical prostatectomy based on the majority voting rule that a sample was assigned as high risk when at least 37 gene pairs of the 74‐GPS voted for high risk; otherwise, low risk. The signature was validated in six independent datasets produced by different platforms. In each of the validation datasets, the Kaplan‐Meier survival analysis showed that the average BFS of the low‐risk group was significantly better than that of the high‐risk group. Analyses of multiomics data of PCa samples from TCGA suggested that both the epigenomic and genomic alternations could cause the reproducible transcriptional differences between the two different prognostic groups. Conclusions The proposed qualitative transcriptional signature can robustly stratify PCa patients after radical prostatectomy into two groups with different recurrence risk and distinct multiomics characteristics. Hence, 74‐GPS may serve as a helpful tool for guiding the management of PCa patients with radical prostatectomy at the individual level.

show abstract

Section: Discussionmentioning

confidence: 99%

A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy

Huang

Zhang

et al. 2020

The Prostate

View full text Add to dashboard Cite

show abstract

“…Importantly, the impact of more aggressive imaging and biopsy interventions have not been found to improve the primary purpose of PCa early detection: a reduction in PCa mortality, though mortality as an endpoint for MRI utilization has not been studied to our knowledge in an AS population. Currently, most men still undergo systematic TRUS biopsy for both initial diagnosis as well as surveillance biopsy, and MRI is not considered standard of care, nor a replacement for systematic biopsy 3, 30 . Finally, the converse point is that among men without elevated PSAD and BMI it may be reasonable to defer first AS biopsy up to 15 months (median interval in the longest tertile).…”

Section: Discussionmentioning

confidence: 99%

“…1, 2 Nonetheless, contemporary data suggest that most with National Comprehensive Cancer Network (NCCN 3 ) low/very-low risk PCa receive definitive therapy, despite lack evidence of improved survival or reduced morbidity. 4,5 …”

Section: Introductionmentioning

confidence: 99%

Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study

et al. 2017

View full text Add to dashboard Cite

Purpose During active surveillance (AS) for localized prostate cancer (PCa), first surveillance biopsy timing varies. We analyzed the Canary Prostate Cancer Active Surveillance Study (PASS), to determine biopsy timing influence on rates of PCa adverse reclassification at first AS biopsy. Materials/Methods Of 1,085 participants in PASS, 421 had <34% cores involved with cancer, Gleason sum ≤6, and thereafter underwent on-study AS biopsy. Reclassification was defined as increase in Gleason sum and/or ≥34% of cores with PCa. First AS biopsy reclassification rates were categorized as <8, 8–13 and >13 months post-diagnosis. Multivariable logistic regression determined association between reclassification and first biopsy timing. Results Of 421 men, 89 (21.1%) experienced reclassification at first AS biopsy. Median time from PCa diagnosis to first AS biopsy was 11 months (IQR 7.8–13.8). Reclassification rates at <8, 8–13 and >13 months were 24%, 19%, and 22%, (p=0.65). On multivariable analysis, compared to men biopsied at <8 months the odds ratios (OR) of reclassification at 8–13 and >13 months were 0.88 (95%CI 0.5,1.6) and 0.95 (95% CI 0.5,1.9), respectively. PSA density ≥0.15 (reference <0.15, OR 1.9 [95%CI 1.1, 4.1]) and body mass index (BMI) ≥35 (reference <25 kg/m2, OR 2.4 [95%CI 1.1,5.7]) were associated with increased odds of reclassification. Conclusions Timing of first AS biopsy was not associated with increased adverse reclassification but PSA density and BMI were. In low-risk patients on AS, it may be reasonable to perform first AS biopsy at a later time, reducing overall cost and morbidity of AS.

show abstract

“…These challenging high-risk situations require recurring and timely follow-up care to prevent harm [7, 9–17, 56]. …”

Section: Methodsmentioning

confidence: 99%

Implementation science for ambulatory care safety: a novel method to develop context-sensitive interventions to reduce quality gaps in monitoring high-risk patients

McDonald

Lisker

et al. 2017

Implementation Sci

View full text Add to dashboard Cite

Background: Missed evidence-based monitoring in high-risk conditions (e.g., cancer) leads to delayed diagnosis. Current technological solutions fail to close this safety gap. In response, we aim to demonstrate a novel method to identify common vulnerabilities across clinics and generate attributes for context-flexible population-level monitoring solutions for widespread implementation to improve quality.

show abstract

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

Cited by 998 publications

References 260 publications

A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy

A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy

Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study

Implementation science for ambulatory care safety: a novel method to develop context-sensitive interventions to reduce quality gaps in monitoring high-risk patients

Contact Info

Product

Resources

About